Strobel, ThomasAhmed, WaseemDe la Sancha, CarloBohm, MatthewFischer, Monika2021-08-092021-08-092020-09-01Strobel, T., Ahmed, W., De la Sancha, C., Bohm, M., & Fischer, M. (2020). IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease. ACG Case Reports Journal, 7(9), e00462. https://doi.org/10.14309/crj.00000000000004622326-3253https://hdl.handle.net/1805/26411Tumor necrosis factor-α (TNF-α)-inhibiting agents are a standard therapy for moderate-to-severe inflammatory bowel disease (IBD). IgA nephropathy in the setting of prolonged exposure to TNF-α inhibitors is a rare, clinically significant adverse event often overlooked by gastroenterologists but well documented in the rheumatologic literature. We present a case series of 3 patients with IBD on TNF-α inhibitors who developed biopsy-proven IgA nephropathy. Clinicians prescribing TNF-α inhibitors to patients with IBD need to be aware of this potential side effect. Therapies with alternative mechanisms of action should instead be considered.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalTumor necrosis factor-αinflammatory bowel diseaseCrohn's diseasegastrointestinal tractulcerative colitisArticle